Welcome to our dedicated page for NextCure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on NextCure stock.
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. The company’s leading product candidate, NC318, is currently in Phase 2 clinical trials for advanced or metastatic solid tumors. NextCure is also advancing NC410, a novel immunomedicine designed to block immune suppression mediated by the immune modulator LAIR-1, and LNCB74, an ADC targeting B7-H4, a clinically validated cancer target. The company's pipeline includes additional antibodies in preclinical development targeting novel immune modulators expressed in inflamed tissue and tumor microenvironments across various cancer types.
NextCure has established significant partnerships including a license agreement with Yale University and a research collaboration with LigaChem Biosciences. Recent updates in their clinical pipeline include promising preclinical data on NC605 for preventing bone loss in patients with severe spinal cord injuries and the publication of a manuscript on the FLRT3-UNC5B pathway as a novel T cell checkpoint in cancer immunotherapy. Their innovative FIND-IO platform continues to discover new immunomedicine targets, expanding their therapeutic potential beyond oncology to chronic inflammatory diseases like COPD.
Financially, NextCure has a solid runway extending into the second half of 2026, focusing resources on high-priority programs such as NC410 in combination therapies and LNCB74, while seeking partners for other clinical and preclinical assets. The company's goal is to address unmet medical needs by providing new treatments for patients who do not respond to existing therapies or experience disease progression, leveraging scientific insights into biological pathways, cell interactions, and tumor microenvironments.
For the latest updates, visit www.nextcure.com
NextCure (Nasdaq: NXTC) provided a business update and reported Q2 2024 financial results. Key highlights include:
1. Completed enrollment of 16 additional ovarian cancer patients in the NC410 + pembrolizumab Phase 1b study.
2. Finished GLP toxicology studies for LNCB74 (B7-H4 ADC), targeting IND submission by year-end.
3. Cash position of $86.4 million, expected to fund operations into H2 2026.
4. Q2 2024 financials: R&D expenses $12.4M, G&A expenses $4.1M, net loss $15.4M.
5. On track to present expanded ovarian cancer cohort data and CRC update in Q4 2024.
6. Advancing NC181 (APOE4) and NC605 (Siglec-15) programs, seeking partnerships for IND filings.
NextCure, a clinical-stage biopharmaceutical company listed on Nasdaq as NXTC, has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
The event is scheduled for June 27, 2024. NextCure will present and host meetings with institutional investors.
A recording of the webcast will be accessible starting at 7 AM ET on the same day through the Investors section of NextCure’s website, www.nextcure.com, and will remain available for 30 days.
NextCure (Nasdaq: NXTC) announced promising results from its Phase 1b study of NC410 in combination with pembrolizumab, presented at ASCO 2024. The study focused on patients with MSS/MSI-L colorectal cancer (CRC) and ovarian cancer. Key findings include a 51% disease control rate in CRC patients and a 43% rate in ovarian cancer patients. Two CRC patients had ongoing partial responses (PR) and a median disease control duration of 5.5 months. In ovarian cancer, three patients experienced PRs with a 43% overall response rate. Adverse events were mostly mild, but 39.5% of patients had Grade ≥3 Treatment Emergent Adverse Events (TEAE), and 4.9% had Grade ≥3 Treatment-Related Adverse Events (TRAE). A poster presentation by Dr. Eric S. Christenson will detail these findings on June 1, 2024, at the ASCO Annual Meeting in Chicago.
NextCure, a clinical-stage biopharmaceutical company, reported its first-quarter 2024 financial results and provided a business update. They highlighted presenting Phase 1b data for NC410 combo with pembro at the ASCO Annual Meeting, showcasing preclinical data from LNCB74 at the AACR Annual Meeting, and having cash of approximately $96.0 million to fund operations into the second half of 2026. The company is focused on developing novel cancer therapies.
FAQ
What is the current stock price of NextCure (NXTC)?
What is the market cap of NextCure (NXTC)?
What is NextCure, Inc. known for?
What are the key products in development at NextCure?
What partnerships does NextCure have?
What is NC318?
How does NC410 work?
What recent achievements has NextCure made?
What is the FIND-IO platform?
What is LNCB74?
What is NextCure’s financial outlook?
Where can I find the latest updates on NextCure?
